Breaking News

Financial Report: Baxter 3Q11

BioScience revenues up 9%

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Baxter 3Q11 3Q Revenues: $3.5 billion (+8%) 3Q Earnings: $576.0 million (+10%) YTD Revenues: $10.3 billion (+10%) YTD Earnings: $1.8 billion (+77%) Comments: BioScience revenues in the quarter were $1.5 billion (+9%), boosted by Gammagard Liquid, certain plasma-based therapeutics, and vaccines. Medical Products sales were $2.0 billion (+7%). 1Q10 included a charge totaling $588 million related to the recall of COLLEAGUE infusion pumps and 3Q10 included an impairment charge of $112 million a...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters